Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

被引:160
作者
Mouton, Johan W. [1 ,2 ,3 ]
Ambrose, Paul G. [4 ]
Canton, Rafael [5 ,6 ]
Drusano, George L. [7 ]
Harbarth, Stephan [8 ]
MacGowan, Alasdair [9 ]
Theuretzbacher, Ursula [10 ]
Turnidge, John [11 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[2] Nijmegen Inst Infect Inflammat & Immun, Nijmegen, Netherlands
[3] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands
[4] Inst Clin Pharmacodynam Inc, Latham, NY USA
[5] Hosp Univ Ramon y Cajal, IRYCIS, Microbiol Serv, Madrid, Spain
[6] Hosp Univ Ramon y Cajal, IRYCIS, CIBERESP, Madrid, Spain
[7] Ordway Res Inst, Albany, NY USA
[8] Geneva Univ Hosp & Med Sch, Geneva, Switzerland
[9] Southmead Hosp, Bristol, Avon, England
[10] Ctr Antiinfect Agents CEFAIA, Vienna, Austria
[11] Womens & Childrens Hosp, SA Pathol, Adelaide, SA, Australia
关键词
PK/PD; Emergence resistance; Breakpoints; Drug development; MONTE-CARLO-SIMULATION; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL RESISTANCE; STAPHYLOCOCCUS-AUREUS; COMBINATION THERAPY; IN-VITRO; BACTERIAL-RESISTANCE; SEPTIC SHOCK; IMPACT; EMERGENCE;
D O I
10.1016/j.drup.2011.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is a growing need to optimize the use of old and new antibiotics to treat serious as well as less serious infections. The topic of how to use pharmacokinetic and pharmacodynamic (PK/PD) knowledge to conserve antibiotics for the future was elaborated on in a workshop of the conference (The conference "The Global Need for Effective Antibiotics - moving towards concerted action", ReAct, Uppsala, Sweden, 2010). The optimization of dosing regimens is accomplished by choosing the dose and schedule that results in the antimicrobial exposure that will achieve the microbiological and clinical outcome desired while simultaneously suppressing emergence of resistance. PK/PD of antimicrobial agents describe how the therapeutic drug effect is dependent on the potency of a drug against a microorganism and the exposure (the concentration of antimicrobial available for effect over time). The description and modeling of these relationships quantitatively then allow for a rational approach to dose optimization and several strategies to that purpose are described. These strategies include not only the dosing regimen itself but also the duration of therapy, preventing collateral damage through inappropriate use and the application of PK/PD in drug development. Furthermore, PK/PD relationships of older antibiotics need to be urgently established. The need for global harmonization of breakpoints is also suggested and would add efficacy to antibiotic therapy. For each of the strategies, a number of priority actions are provided. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:107 / 117
页数:11
相关论文
共 86 条
[1]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[2]   Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future - Insights from the society of infectious diseases pharmacists [J].
Ambrose, PG .
PHARMACOTHERAPY, 2006, 26 (01) :129-134
[3]   The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs:: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae [J].
Ambrose, PG ;
Grasela, DM .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :151-157
[4]   Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals [J].
Bergstrom, CT ;
Lo, M ;
Lipsitch, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13285-13290
[5]   Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms [J].
Bhat, Sunil V. ;
Peleg, Anton Y. ;
Lodise, Thomas P., Jr. ;
Shutt, Kathleen A. ;
Capitano, Blair ;
Potoski, Brian A. ;
Paterson, David L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) :4390-4395
[6]   Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem [J].
Bhavnani, SM ;
Hammel, JP ;
Cirincione, BB ;
Wikler, MA ;
Ambrose, PG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3944-3947
[7]  
Blázquez J, 2003, CLIN INFECT DIS, V37, P1201, DOI 10.1086/378810
[8]   A brief introduction to Monte Carlo simulation [J].
Bonate, PL .
CLINICAL PHARMACOKINETICS, 2001, 40 (01) :15-22
[9]   Use of antimicrobial prophylaxis for major surgery - Baseline results from The National Surgical Infection Prevention Project [J].
Bratzler, DW ;
Houck, PM ;
Richards, C ;
Steele, L ;
Dellinger, EP ;
Fry, DE ;
Wright, C ;
Ma, A ;
Carr, K ;
Red, L .
ARCHIVES OF SURGERY, 2005, 140 (02) :174-182
[10]   Antibiotic cycling or rotation: a systematic review of the evidence of efficacy [J].
Brown, EM ;
Nathwani, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :6-9